Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

Lilly Weakens on Data Reveal for Oral Obesity Candidate

Sophnelo showed efficacy in reducing lupus disease activity, while Fasenra did not significantly reduce COPD attacks, according to AstraZeneca's recent Phase 3 trials.

Summary by Pharmaphorum
Eli Lilly is preparing to file for approval of its oral weight-loss drug orforglipron before year-end, but not all are convinced by the data.

3 Articles

PharmaphorumPharmaphorum
Center

Lilly weakens on data reveal for oral obesity candidate

Eli Lilly is preparing to file for approval of its oral weight-loss drug orforglipron before year-end, but not all are convinced by the data.

Read Full Article
biopharmadive.combiopharmadive.com
Center

Lilly, Novo showcase new obesity drug data; Fasenra falls short in COPD

Lilly claimed success in a head-to-head trial of oral GLP-1 drugs. Elsewhere, Novo planned a new weight loss trial and an AI-focused startup raised its second “megaround.”

Read Full Article
headlinemoney.co.ukheadlinemoney.co.uk

AstraZeneca: Fasenra data disappoints on COPD, but Tulip trial offers hope for Lupus sufferers

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources are Center
100% Center

Factuality 

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

headlinemoney.co.uk broke the news in on Wednesday, September 17, 2025.
Sources are mostly out of (0)

Similar News Topics

Eli Lilly icon

Eli Lilly

News
For You
SearchBlindspotLocal